Advanced in Acute Myeloid Leukemia (AML)

Bjorn Hackanson

Freiburg, BW, DE 
Advanced in Acute Myeloid Leukemia (AML)
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Bjorn Hackanson practices in Freiburg, Germany. Hackanson is rated as an Advanced expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). Their top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Lung Cancer, and Smith-Magenis Syndrome.

Their clinical research consists of co-authoring 35 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 22 articles and participated in 1 clinical trial in the study of Acute Myeloid Leukemia (AML).

Locations

Freiburg, BW, Germany
Other Locations
Augsburg, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Enrollment Status: Unknown
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Daunorubicin, Cytarabine, Idarubicin, Etoposide
Study Phase: Phase 3
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 2 Less Clinical Trials

35 Total Publications

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
Journal: European journal of haematology
Published: May 27, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hackanson's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile